- Recipharm reported reductions of 20% in Scope 1 and 74% in Scope 2 emissions versus its 2021 baseline.
- The company achieved 100% renewable electricity across all sites and advanced waste and water efficiency initiatives.
Recipharm has reported its 2025 sustainability results, outlining progress across emissions reduction, resource efficiency, and environmental performance within its global contract manufacturing operations.
The company stated that it reduced Scope 1 greenhouse gas emissions by 20% and Scope 2 emissions by 74% compared to its 2021 baseline. It also maintained 100% renewable electricity across all of its sites, reflecting ongoing efforts to reduce operational environmental impact.
Recipharm reported improvements in water and waste management, including a 13% reduction in total water withdrawal since 2022 and the elimination of surface water withdrawal. In waste management, 63% of incinerated waste was recovered for energy, and 13 out of 17 sites are now landfill-free, with a target to eliminate landfill use entirely by 2027.
The company also received external recognition for its sustainability performance, achieving a B rating for Climate Change, an A- for Water Security, and an A for Supplier Engagement Assessment from CDP. Recipharm stated that these ratings reflect progress in environmental and supply chain initiatives.
“Sustainability is a defining part of who we are at Recipharm. In 2025, our commitment translated into tangible progress and clear leadership, demonstrating that responsible pharmaceutical development and manufacturing can go hand in hand with strong operational performance.”
Greg Behar, CEO of Recipharm
